Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024
Stifel Maintains Pulmonx(LUNG.US) With Buy Rating, Maintains Target Price $17
Analysts Are Bullish on Top Healthcare Stocks: Pulmonx (LUNG), Omnicell (OMCL)
Is Pulmonx (NASDAQ:LUNG) A Risky Investment?
Pulmonx Director French Glendon E. III Sells $161,800 in Company Stock
Express News | Pulmonx Corp - 5-Year Data Show Durable Benefits of Zephyr Valves
Express News | Pulmonx Announces Presentation of Clinical Data From the Aeriseal® Convert Trial and 5-Year Follow-up Data From the Liberate Study at the European Respiratory Society Congress 2024
Pulmonx Announces Presentation of Clinical Data From the AeriSeal CONVERT Trial and 5-Year Follow-up Data From the LIBERATE Study at the European Respiratory Society Congress 2024
Wells Fargo Reaffirms Their Hold Rating on Pulmonx (LUNG)
Wells Fargo Maintains Pulmonx(LUNG.US) With Hold Rating, Maintains Target Price $10
Wells Fargo analyst Larry Biegelsen maintains $Pulmonx(LUNG.US)$ with a hold rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 64.6% and a
Aeriseal's Market Potential and Safety Profile: Justifying a Hold Rating for Pulmonx
CEO, President & Director of Pulmonx Picks Up 6.9% More Stock
Pulmonx Shares Rise After Disclosure of Stock Purchases by CEO
Pulmonx (LUNG) Gets a Buy From Lake Street
Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference
Buy Rating Affirmed for Pulmonx: Strong Growth and Promising Clinical Advancements
Pulmonx | 10-Q: Q2 2024 Earnings Report
Analysts Are Updating Their Pulmonx Corporation (NASDAQ:LUNG) Estimates After Its Second-Quarter Results
Pulmonx Is Maintained at Buy by Canaccord Genuity
Pulmonx Price Target Cut to $10.00/Share From $14.00 by Wells Fargo